Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01422382 · ClinicalTrials.gov registry record · Phase 4

Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin

A Phase 4 study of Healthy, sponsored by Kowa Research Institute.

Completed
Registry status
Phase 4
Development phase
28
Enrollment target
1
Study location

NCT01422382 is a Phase 4 study of Healthy that has completed, run by Kowa Research Institute. The registered enrollment target is 28 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01422382, a Phase 4 study of Healthy, has completed, sponsored by Kowa Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.

Conditions Studied

Interventions

  • DRUG Pitavastatin (NK-104)
  • DRUG Diltiazem (Cardizem LA) 240 mg QD

Study Locations (1)

Texas

  • - Austin

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2011-05
Est. Completion 2011-07
Phase Phase 4

Sponsor

Kowa Research Institute

44 total trials

What the Registry Record Tells You About NCT01422382

The ClinicalTrials.gov registry entry for NCT01422382 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Pitavastatin (NK-104) is the first listed.

NCT01422382 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01422382 about?

NCT01422382 is a clinical study titled "Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin". This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.

What is the current status of trial NCT01422382?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2011-05. Estimated completion is 2011-07.

What conditions does trial NCT01422382 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01422382?

The interventions under investigation include: Pitavastatin (NK-104) (DRUG), Diltiazem (Cardizem LA) 240 mg QD (DRUG).

Who is sponsoring clinical trial NCT01422382?

This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01422382 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.